81 related articles for article (PubMed ID: 11225997)
1. Rituximab as first-line systemic therapy for patients with low-grade lymphoma.
Hainsworth JD
Semin Oncol; 2000 Dec; 27(6 Suppl 12):25-9. PubMed ID: 11225997
[TBL] [Abstract][Full Text] [Related]
2. Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase II trial of the Minnie Pearl Cancer Research Network.
Hainsworth JD; Litchy S; Barton JH; Houston GA; Hermann RC; Bradof JE; Greco FA;
J Clin Oncol; 2003 May; 21(9):1746-51. PubMed ID: 12721250
[TBL] [Abstract][Full Text] [Related]
3. Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin's lymphoma--a randomized phase II trial of the Minnie Pearl Cancer Research Network.
Hainsworth JD; Litchy S; Shaffer DW; Lackey VL; Grimaldi M; Greco FA
J Clin Oncol; 2005 Feb; 23(6):1088-95. PubMed ID: 15657401
[TBL] [Abstract][Full Text] [Related]
4. Rituximab plus short-duration chemotherapy as first-line treatment for follicular non-Hodgkin's lymphoma: a phase II trial of the minnie pearl cancer research network.
Hainsworth JD; Litchy S; Morrissey LH; Andrews MB; Grimaldi M; McCarty M; Greco FA
J Clin Oncol; 2005 Mar; 23(7):1500-6. PubMed ID: 15632411
[TBL] [Abstract][Full Text] [Related]
5. Overview of the clinical development of rituximab: first monoclonal antibody approved for the treatment of lymphoma.
Grillo-López AJ; White CA; Varns C; Shen D; Wei A; McClure A; Dallaire BK
Semin Oncol; 1999 Oct; 26(5 Suppl 14):66-73. PubMed ID: 10561020
[TBL] [Abstract][Full Text] [Related]
6. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ
Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686
[TBL] [Abstract][Full Text] [Related]
7. A phase 2 study of rituximab in combination with recombinant interleukin-2 for rituximab-refractory indolent non-Hodgkin's lymphoma.
Khan KD; Emmanouilides C; Benson DM; Hurst D; Garcia P; Michelson G; Milan S; Ferketich AK; Piro L; Leonard JP; Porcu P; Eisenbeis CF; Banks AL; Chen L; Byrd JC; Caligiuri MA
Clin Cancer Res; 2006 Dec; 12(23):7046-53. PubMed ID: 17145827
[TBL] [Abstract][Full Text] [Related]
8. Rituximab therapy for patients with newly diagnosed, advanced-stage, follicular grade I non-Hodgkin's lymphoma: a phase II trial in the North Central Cancer Treatment Group.
Witzig TE; Vukov AM; Habermann TM; Geyer S; Kurtin PJ; Friedenberg WR; White WL; Chalchal HI; Flynn PJ; Fitch TR; Welker DA
J Clin Oncol; 2005 Feb; 23(6):1103-8. PubMed ID: 15657404
[TBL] [Abstract][Full Text] [Related]
9. Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma: interim follow-up of a multicenter phase II trial.
Hainsworth JD
Semin Oncol; 2002 Feb; 29(1 Suppl 2):25-9. PubMed ID: 11842385
[TBL] [Abstract][Full Text] [Related]
10. Optimizing the use of rituximab for treatment of B-cell non-Hodgkin's lymphoma: a benefit-risk update.
Kunkel L; Wong A; Maneatis T; Nickas J; Brown T; Grillo-López A; Benyunes M; Grobman B; Dillman RO
Semin Oncol; 2000 Dec; 27(6 Suppl 12):53-61. PubMed ID: 11226001
[TBL] [Abstract][Full Text] [Related]
11. High-dose rituximab therapy in chronic lymphocytic leukemia.
Keating M; O'Brien S
Semin Oncol; 2000 Dec; 27(6 Suppl 12):86-90. PubMed ID: 11226005
[TBL] [Abstract][Full Text] [Related]
12. Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin's lymphoma.
Leonard JP; Coleman M; Ketas J; Ashe M; Fiore JM; Furman RR; Niesvizky R; Shore T; Chadburn A; Horne H; Kovacs J; Ding CL; Wegener WA; Horak ID; Goldenberg DM
J Clin Oncol; 2005 Aug; 23(22):5044-51. PubMed ID: 15955901
[TBL] [Abstract][Full Text] [Related]
13. Multicenter phase II trial of immunotherapy with the humanized anti-CD22 antibody, epratuzumab, in combination with rituximab, in refractory or recurrent non-Hodgkin's lymphoma.
Strauss SJ; Morschhauser F; Rech J; Repp R; Solal-Celigny P; Zinzani PL; Engert A; Coiffier B; Hoelzer DF; Wegener WA; Teoh NK; Goldenberg DM; Lister TA
J Clin Oncol; 2006 Aug; 24(24):3880-6. PubMed ID: 16864854
[TBL] [Abstract][Full Text] [Related]
14. Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma.
Rummel MJ; Al-Batran SE; Kim SZ; Welslau M; Hecker R; Kofahl-Krause D; Josten KM; Dürk H; Rost A; Neise M; von Grünhagen U; Chow KU; Hansmann ML; Hoelzer D; Mitrou PS
J Clin Oncol; 2005 May; 23(15):3383-9. PubMed ID: 15908650
[TBL] [Abstract][Full Text] [Related]
15. Maintenance therapy for low-grade lymphomas: has the time come?
Cartron G; Solal-Céligny P
Curr Opin Oncol; 2007 Sep; 19(5):425-32. PubMed ID: 17762565
[TBL] [Abstract][Full Text] [Related]
16. A pilot study of the anti-CD20 monoclonal antibody rituximab in patients with refractory immune thrombocytopenia.
Saleh MN; Gutheil J; Moore M; Bunch PW; Butler J; Kunkel L; Grillo-López AJ; LoBuglio AF
Semin Oncol; 2000 Dec; 27(6 Suppl 12):99-103. PubMed ID: 11226008
[TBL] [Abstract][Full Text] [Related]
17. Rituximab in combination with fludarabine chemotherapy in low-grade or follicular lymphoma.
Czuczman MS; Koryzna A; Mohr A; Stewart C; Donohue K; Blumenson L; Bernstein ZP; McCarthy P; Alam A; Hernandez-Ilizaliturri F; Skipper M; Brown K; Chanan-Khan A; Klippenstein D; Loud P; Rock MK; Benyunes M; Grillo-Lopez A; Bernstein SH
J Clin Oncol; 2005 Feb; 23(4):694-704. PubMed ID: 15681517
[TBL] [Abstract][Full Text] [Related]
18. The role of mitoxantrone in the treatment of indolent lymphomas.
Hagemeister F; Cabanillas F; Coleman M; Gregory SA; Zinzani PL
Oncologist; 2005 Feb; 10(2):150-9. PubMed ID: 15709217
[TBL] [Abstract][Full Text] [Related]
19. Systemic eight-cycle anti-CD20 monoclonal antibody (rituximab) therapy in primary cutaneous B-cell lymphomas--an applicational observation.
Gellrich S; Muche JM; Wilks A; Jasch KC; Voit C; Fischer T; Audring H; Sterry W
Br J Dermatol; 2005 Jul; 153(1):167-73. PubMed ID: 16029344
[TBL] [Abstract][Full Text] [Related]
20. [Efficacy of rituximab-containing regimens on indolent B-cell lymphoma--a report of 34 cases].
Xia ZJ; Wang FH; Huang HQ; Luo HY; Li YH; Lin TY; Jiang WQ; Guan ZZ
Ai Zheng; 2006 Apr; 25(4):490-4. PubMed ID: 16613687
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
